This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Zeria Pharmaceutical Co., Ltd.
Drug Names(s): acotiamide hydrochloride hydrate, Z338, YM443, Z-338
Description: YM443 is an acetylcholine level enhancer. It increases GI motility by promoting the release of acetylcholine and is expected to be effective in relieving subjective symptoms associated with functional GI disorders. YM443 enhances gastric accommodation and gastric emptying, the two factors which have been implicated in the cause of functional dyspepsia. YM443 is being developed for the treatment of post meal fullness, bloating and early satiety in functional dyspepsia.
Deal Structure: In July 2002, Zeria Pharmaceutical Co. and Yamanouchi Pharmaceutical Co. signed a letter of intent regarding the development and marketing of Z-338, which Zeria has synthesized and is developing as a gastroprokinetic agent. Under this agreement, Zeria grants the exclusive development and marketing rights in the US and Canada to Yamanouchi, as well as the first refusal right in the licensing in the EU and Japan. Zeria will retain the right to develop and market the compound in all countries other than the US and Canada.
In April 2005, Yamanouchi and Fujisawa merged to form Astellas Pharma.
In March 2008, Astellas Pharma announced that Astellas and Zeria Pharmaceutical concluded the agreement for the co-development and co-marketing of Z-338/YM443 (acotiamide hydrochloride) in Japan. Based on this agreement, Zeriq will obtain marketing approval, and both companies will co-market the product under the single brand name.
In Feburary 2010, Astellas announced that it had terminated...See full deal structure in Biomedtracker
Partners: Astellas Pharma, Inc.
Additional information available to subscribers only: